A gastroenterologist and microbiome researcher who has promoted hydroxychloroquine and ivermectin as COVID treatments has lost a paper after a sleuth reported differences between the article and the registered protocol of the clinical trial it purported to describe. The retracted article, on detecting SARS-CoV-2 in fecal samples, was published in Gut Pathogens in January 2021. It marks the fourth retraction for study coauthor Sabine Hazan.

Hazan is founder and CEO of ProgenaBiome, a laboratory in Ventura, Calif., advertising clinical trials exploring the role of the gut microbiome in conditions including autism and Alzheimer’s disease, as well as COVID. She is also CEO of Ventura Clinical Trials, which lists dozens of pharmaceutical and biotech companies among its clients. Hazan has nearly 200,000 followers on X, where she reposts messages from the account "cienceGuardians" critical of PubPeer and sleuths.

Source https://retractionwatch.com/2025/07/22/microbiome-company-ceo-sabine-hazan-retraction-covid-sarscov2-fecal-samples-gut-pathogens/

Another high-profile case has interested scientists. Read now